LifeMD Securities Suit Intensifies as Lead Plaintiff Deadline Nears

Plaintiffs allege LifeMD concealed rising customer acquisition costs alongside elevated refunds at RexMD, leading to a 44% share plunge.

Overview

Multiple investor firms, including Rosen, Pomerantz, Faruqi & Faruqi, Berger Montague, and Hagens Berman, are urging eligible shareholders to seek lead-plaintiff status by October 27, 2025.
The federal case, captioned Johnston v. LifeMD, Inc., is proceeding in the Eastern District of New York and targets purchases within the May 7 to August 5, 2025 class period.
Filings claim the company overstated its competitive position and raised 2025 guidance without properly accounting for higher acquisition costs in RexMD and for obesity drugs such as Wegovy and Zepbound.
LifeMD cut its full-year outlook with its August 5, 2025 quarterly release, after which shares fell roughly 44.8% on August 6 following disclosures of operational strains at RexMD.
No class has been certified, and firms are also soliciting tips from whistleblowers and former employees as investors consider motions for appointment as lead plaintiff.